Company facts
- Industry
- N/A
- Headquarters
- Philadelphia, Pennsylvania
- Most recent report
- 8-K, filed Sep 12, 2023
- Incorporated
- Massachusetts
- Filings on record
- 519 filings
- On EDGAR
- CIK 884121
- Fiscal year ends
- September
- Filer status
- N/A
News 8 of 10
Proxies 8 of 57
- DEF 14A Proxy statement for a shareholder vote Apr 7, 2026
- DEF 14A Proxy statement for a shareholder vote Apr 14, 2025
- DEFA14A Extra proxy material May 24, 2024
- DEF 14A Proxy statement for a shareholder vote Apr 22, 2024
- DEFA14A Extra proxy material Oct 5, 2023
- DEFA14A Extra proxy material Oct 4, 2023
- DEFA14A Extra proxy material Oct 2, 2023
- DEFA14A Extra proxy material Sep 15, 2023
Ownership 8 of 185
- SCHEDULE 13G/A Large holder reported a passive stake, amended Oct 14, 2026
- 4 Insider reported a trade Jul 20, 2026
- 3 Insider reported their initial holding Jun 11, 2026
- SCHEDULE 13G/A Large holder reported a passive stake, amended Mar 6, 2026
- SCHEDULE 13D/A Large holder reported an active stake, amended Feb 23, 2026
- SCHEDULE 13D/A Large holder reported an active stake, amended Feb 11, 2026
- SCHEDULE 13D/A Large holder reported an active stake, amended Jan 8, 2026
- 3 Insider reported their initial holding Dec 19, 2025
Other 8 of 267
Everything here comes from abrdn Life Sciences Investors's own filings on SEC EDGAR. The filing list is rechecked every hour.